Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Cell-Based Therapies in Vascularized Composite Allotransplantation
Krishna S. Vyas
1
Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota
,
Anita T. Mohan
1
Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota
,
Shane D. Morrison
2
Division of Plastic Surgery, Department of Surgery, University of Washington, Seattle, Washington
,
Duy C. Tran
3
Stanford University School of Medicine, Stanford, California
,
Samir Mardini
1
Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota
› InstitutsangabenFunding and Financial Disclosures The authors have no financial disclosures to declare and there was no funding obtained for the production of this article.
Background Dendritic cells (DCs) are bone marrow-derived, professional antigen-presenting cells with tolerogenic function. The ability of DCs to regulate alloantigen-specific T cell responses and to promote tolerance has aligned them ideally for a role in vascularized composite allotransplantation (VCA). In this study, we summarize the current evidence for DC therapies for tolerance induction to alleviate the requirement for chronic immunosuppression.
Method A comprehensive and structured review of manuscripts published on VCA was performed using the MEDLINE and PubMed databases. All eligible studies published from the year 2000 to 2017 were included in the final results.
Result Nineteen original preclinical and clinical studies that employed cell therapy for VCA were included in this review. In vivo DC therapy was found to direct the alloimmune response toward either transplant rejection or tolerance in VCA models. While injection of mature DCs rapidly increases T-cell activity in humans and promotes transplant rejection, the injection of immature DCs acts as an immunosuppressant and inhibits T-cell activity. In addition to immature DCs, mesenchymal stem cells were also found to have a positive effect on allotransplantation of solid organs and bone marrow via cytokine expression which decreases the alloreactive effector lymphocytes and increases CD4+/CD25+/FoxP3 Tregs. Despite the promising findings, the efficacy of cell-based therapies varies greatly across studies, partly due to different methods of cell isolation and purification techniques, source, route and timing of administration, and combination immunosuppressive therapy.
Conclusion Additional research is needed to evaluate the efficacy and safety of DC and other cell-based therapeutic measures in human allotransplant recipients. Future direction will focus on the development of novel methods to reduce immunosuppression and develop more individualized management, as well as the clinical application of basic research in the mechanisms of immunologic tolerance.
5
Steinman RM,
Cohn ZA.
Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137 (05) 1142-1162
6
Legge KL,
Gregg RK,
Maldonado-Lopez R.
, et al. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med 2002; 196 (02) 217-227
10
Cools N,
Ponsaerts P,
Van Tendeloo VF,
Berneman ZN.
Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 2007; 82 (06) 1365-1374
14
Leishman AJ,
Silk KM,
Fairchild PJ.
Pharmacological manipulation of dendritic cells in the pursuit of transplantation tolerance. Curr Opin Organ Transplant 2011; 16 (04) 372-378
15
van Kooten C,
Lombardi G,
Gelderman KA.
, et al. Dendritic cells as a tool to induce transplantation tolerance: obstacles and opportunities. Transplantation 2011; 91 (01) 2-7
16
Lu L,
Li W,
Fu F.
, et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997; 64 (12) 1808-1815
17
Thomson AW,
Lu L,
Subbotin VM.
, et al. In vitro propagation and homing of liver-derived dendritic cell progenitors to lymphoid tissues of allogeneic recipients. Implications for the establishment and maintenance of donor cell chimerism following liver transplantation. Transplantation 1995; 59 (04) 544-551
18
Terness P,
Kleist C,
Simon H.
, et al. Mitomycin C-treated antigen-presenting cells as a tool for control of allograft rejection and autoimmunity: from bench to bedside. Hum Immunol 2009; 70 (07) 506-512
19
Oluwole OO,
Depaz HA,
Gopinathan R.
, et al. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific permanent acceptance of rat islets by adoptive transfer of allopeptide-pulsed host myeloid and thymic dendritic cells. Diabetes 2001; 50 (07) 1546-1552
20
Mirenda V,
Berton I,
Read J.
, et al. Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004; 15 (04) 987-997
22
Kuo YR,
Huang CW,
Goto S.
, et al. Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation. J Surg Res 2009; 153 (02) 317-325
24
Horibe EK,
Sacks J,
Unadkat J.
, et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008; 18 (04) 307-318
25
Eun SC,
Baek RM,
Park CG.
Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. Transplant Proc 2013; 45 (05) 1792-1796
26
Liu F,
Luo X,
Lan S.
, et al. Immunosuppression with a combination of triptolide and cyclosporin A in rat vascularized groin flap allotransplantation. Plast Reconstr Surg 2013; 131 (03) 343e-350e
27
Wang Y,
Zheng Z,
Zhu X.
, et al. The amelioration of composite tissue allograft rejection by TIM-3-modified dendritic cell: regulation of the balance of regulatory and effector T cells. Immunol Lett 2016; 169: 15-22
28
Yamano T,
Watanabe S,
Hasegawa H.
, et al. Ex vivo-expanded DCs induce donor-specific central and peripheral tolerance and prolong the acceptance of donor skin grafts. Blood 2011; 117 (09) 2640-2648
29
Turnquist HR,
Raimondi G,
Zahorchak AF,
Fischer RT,
Wang Z,
Thomson AW.
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178 (11) 7018-7031
30
Fischer RT,
Turnquist HR,
Wang Z,
Beer-Stolz D,
Thomson AW.
Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8(+) T cells in vitro and in vivo. Transpl Immunol 2011; 25 (01) 20-26
32
Kuo YR,
Chen CC,
Goto S,
Lin PY,
Wei FC,
Chen CL.
Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation. Clin Dev Immunol 2012; 2012 (12) 854846
33
Djouad F,
Charbonnier LM,
Bouffi C.
, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25 (08) 2025-2032
35
Li M,
Sun K,
Welniak LA,
Murphy WJ.
Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Expert Opin Pharmacother 2008; 9 (13) 2305-2316
40
Melief SM,
Zwaginga JJ,
Fibbe WE,
Roelofs H.
Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2013; 2 (06) 455-463
41
Cui L,
Yin S,
Liu W,
Li N,
Zhang W,
Cao Y.
Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng 2007; 13 (06) 1185-1195
42
Fang B,
Song Y,
Lin Q.
, et al. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 2007; 11 (07) 814-817
43
Wan CD,
Cheng R,
Wang HB,
Liu T.
Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int 2008; 7 (01) 29-33
46
Gonzalez-Rey E,
Anderson P,
González MA,
Rico L,
Büscher D,
Delgado M.
Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58 (07) 929-939
48
Gonzalez-Rey E,
Gonzalez MA,
Varela N.
, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010; 69 (01) 241-248
49
Engela AU,
Baan CC,
Dor FJ,
Weimar W,
Hoogduijn MJ.
On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol 2012; 3: 126
50
Izadpanah R,
Trygg C,
Patel B.
, et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem 2006; 99 (05) 1285-1297
51
Liu TM,
Martina M,
Hutmacher DW,
Hui JH,
Lee EH,
Lim B.
Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells 2007; 25 (03) 750-760
52
Noël D,
Caton D,
Roche S.
, et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 2008; 314 (07) 1575-1584
54
De Miguel MP,
Fuentes-Julián S,
Blázquez-Martínez A.
, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12 (05) 574-591
55
Figueroa FE,
Carrión F,
Villanueva S,
Khoury M.
Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res 2012; 45 (03) 269-277
58
Casiraghi F,
Azzollini N,
Todeschini M.
, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12 (09) 2373-2383
60
de Girolamo L,
Lucarelli E,
Alessandri G.
, et al; Italian Mesenchymal Stem Cell Group. Mesenchymal stem/stromal cells: a new “cells as drugs” paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des 2013; 19 (13) 2459-2473
63
Hong ZF,
Huang XJ,
Yin ZY,
Zhao WX,
Wang XM.
Immunosuppressive function of bone marrow mesenchymal stem cells on acute rejection of liver allografts in rats. Transplant Proc 2009; 41 (01) 403-409
64
Inoue S,
Popp FC,
Koehl GE.
, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81 (11) 1589-1595
65
Itakura S,
Asari S,
Rawson J.
, et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant 2007; 7 (02) 336-346
66
Kuo YR,
Chen CC,
Goto S.
, et al. Modulation of immune response and T-cell regulation by donor adipose-derived stem cells in a rodent hind-limb allotransplant model. Plast Reconstr Surg 2011; 128 (06) 661e-672e
68
Lawitschka A,
Ball L,
Peters C.
Nonpharmacologic treatment of chronic graft-versus-host disease in children and adolescents. Biol Blood Marrow Transplant 2012; 18 (1, Suppl): S74-S81
69
Le Blanc K,
Frassoni F,
Ball L.
, et al; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371 (9624): 1579-1586
70
Pan H,
Zhao K,
Wang L.
, et al. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation. J Surg Res 2010; 160 (02) 315-324
73
Zhou HP,
Yi DH,
Yu SQ.
, et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006; 38 (09) 3046-3051
74
Plock JA,
Schnider JT,
Solari MG,
Zheng XX,
Gorantla VS.
Perspectives on the use of mesenchymal stem cells in vascularized composite allotransplantation. Front Immunol 2013; 4: 175
75
Kuo YR,
Chen CC,
Shih HS.
, et al. Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plast Reconstr Surg 2011; 127 (02) 569-579
77
Jeong SH,
Ji YH,
Yoon ES.
Immunosuppressive activity of adipose tissue-derived mesenchymal stem cells in a rat model of hind limb allotransplantation. Transplant Proc 2014; 46 (05) 1606-1614
79
Plock JA,
Schnider JT,
Schweizer R.
, et al. The influence of timing and frequency of adipose-derived mesenchymal stem cell therapy on immunomodulation outcomes after vascularized composite allotransplantation. Transplantation 2017; 101 (01) e1-e11
81
Aksu AE,
Horibe E,
Sacks J.
, et al. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol 2008; 127 (03) 348-358
82
Kuo YR,
Chen CC,
Goto S.
, et al. Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One 2012; 7 (04) e35459
83
Zhou Y,
Shan J,
Li Y.
, et al. Adoptive transfusion of tolerance dendritic cells prolongs the survival of skin allografts in mice: a systematic review. J Evid Based Med 2013; 6 (02) 90-103
84
Eggenhofer E,
Benseler V,
Kroemer A.
, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297
85
Rombouts WJ,
Ploemacher RE.
Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17 (01) 160-170
86
Wagner W,
Horn P,
Castoldi M.
, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008; 3 (05) e2213
88
Vacanti V,
Kong E,
Suzuki G,
Sato K,
Canty JM,
Lee T.
Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol 2005; 205 (02) 194-201
90
Berger TG,
Schulze-Koops H,
Schäfer M,
Müller E,
Lutz MB.
Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro. PLoS One 2009; 4 (08) e6645
91
Moreau A,
Chiffoleau E,
Beriou G.
, et al. Superiority of bone marrow-derived dendritic cells over monocyte-derived ones for the expansion of regulatory T cells in the macaque. Transplantation 2008; 85 (09) 1351-1356
93
Lutz MB,
Suri RM,
Niimi M.
, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30 (07) 1813-1822
94
Chitta S,
Santambrogio L,
Stern LJ.
GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. Immunol Lett 2008; 116 (01) 41-54
95
Gregori S,
Tomasoni D,
Pacciani V.
, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116 (06) 935-944
96
Moreau A,
Varey E,
Bériou G.
, et al. Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials. Front Immunol 2012; 3: 218
97
Correale P,
Campoccia G,
Tsang KY.
, et al. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer 2001; 37 (07) 892-902
98
Redman BG,
Chang AE,
Whitfield J.
, et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 2008; 31 (06) 591-598
99
Dhodapkar MV,
Steinman RM,
Krasovsky J,
Munz C,
Bhardwaj N.
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193 (02) 233-238
101
Giannoukakis N,
Phillips B,
Finegold D,
Harnaha J,
Trucco M.
Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34 (09) 2026-2032
103
Harry RA,
Anderson AE,
Isaacs JD,
Hilkens CM.
Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010; 69 (11) 2042-2050